India's Lupin launches generic TriCor in U.S.
MUMBAI Nov 20 (Reuters) - Indian drugmaker Lupin Ltd said on Tuesday it launched a generic version of Abbott Laboratories' cholesterol lowering drug TriCor in the United States.
Lupin got its generic fenofibrate drug approved by the U.S. Food and Drug Administration last December.
Tricor tablets have annual sales of $1.26 billion in the United States, Lupin said in a statement.
Valued $4.46 billion, shares in Lupin closed 1.11 percent up at 568.15 rupees on Tuesday, when the Mumbai stock market was almost flat.
- Pennsylvania newlyweds "just wanted to murder someone together:" police
- WTO overcomes last minute hitch to reach its first global trade deal
- Colorado baker discriminated by denying gay couple wedding cake: judge
- U.S. freeze shows no sign of weekend melt after deadly storm
- Flights delayed as air pollution hits record in Shanghai